HR+/HER2- Advanced Breast Cancer
Authored by Ilana Schlam, published on 2026-04-13 18:09:39.0
HR+/HER2- advanced disease
PD on adjuv ET or within 12 months of ET
PIK3CA mut.
Palbo + fulvestrant + Inavolisib (INAVO120)
PIK3CA, PTEN, AKT alteration
Capivasertib + ET CAPItello-291
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
ESR1 mut.
Elacestrant - EMERALD / Imlunestrant - EMBER-3
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
gBRCA 1/2 mut.
PARPi (Ola, Tal) OLYMPIAD, EMBRACA
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
PIK3CA mut.
Alpelisib + ET SOLAR-1, BYLieve
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
PIK3CA wt
CDK4/6 inhibitor + endocrine therapy
PIK3CA, PTEN, AKT alteration
Capivasertib + ET CAPItello-291
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
ESR1 mut.
Elacestrant - EMERALD / Imlunestrant - EMBER-3
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
gBRCA 1/2 mut.
PARPi (Ola, Tal) OLYMPIAD, EMBRACA
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
PIK3CA mut.
Alpelisib + ET SOLAR-1, BYLieve
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
De novo PD, 1L on adjuv or after adjuv ET
CDK4/6 inhibitor + endocrine therapy
PIK3CA, PTEN, AKT alteration
Capivasertib + ET CAPItello-291
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
ESR1 mut.
Elacestrant - EMERALD / Imlunestrant - EMBER-3
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
gBRCA 1/2 mut.
PARPi (Ola, Tal) OLYMPIAD, EMBRACA
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
PIK3CA mut.
Alpelisib + ET SOLAR-1, BYLieve
None of the above or after progression in 1L lines of therapy from prior
Everolimus, AI or Fulvestrant
HER2 null
Chemo
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 ultralow IHC 0
T-DXd*** DESTINY-Breast06
Dato-DXd Tropion Breast 01***
Chemo
Sacituzumab govitecan TROPiCS***
Chemo
HER2 low HER2 1-2+
T-DXd*** DESTINY-Breast06
T-DXd*** DESTINY-Breast 04
Sacituzumab govitecan TROPiCS***
Dato-DXd Tropion Breast 01***
Chemo
Chemo
tos
privacy
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (MONALEESA-2)
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3)
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2)
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291)
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (EMERALD)
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02)
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]